Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Prevalence of risk factors for statin-induced myopathy in rheumatoid arthritis patients.

Toms TE, Smith JP, Panoulas VF, Douglas KM, Saratzis AN, Kitas GD.

Musculoskeletal Care. 2010 Mar;8(1):2-9. doi: 10.1002/msc.160.

PMID:
19642078
2.

Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.

Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJ, Carleton BC, Kastelein JJ, Hayden MR.

Pharmacogenomics J. 2012 Jun;12(3):233-7. doi: 10.1038/tpj.2010.92. Epub 2011 Jan 18.

PMID:
21243006
3.

SLCO1B1 variants and statin-induced myopathy--a genomewide study.

SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R.

N Engl J Med. 2008 Aug 21;359(8):789-99. doi: 10.1056/NEJMoa0801936. Epub 2008 Jul 23.

4.

SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group.

Santos PC, Soares RA, Nascimento RM, Machado-Coelho GL, Mill JG, Krieger JE, Pereira AC.

BMC Med Genet. 2011 Oct 12;12:136. doi: 10.1186/1471-2350-12-136.

5.

SLCO1B1 variants and statin-induced myopathy.

Vladutiu GD, Isackson PJ.

N Engl J Med. 2009 Jan 15;360(3):304. doi: 10.1056/NEJMc081975. No abstract available.

6.
7.

SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.

Hubáček JA, Dlouhá D, Adámková V, Zlatohlavek L, Viklický O, Hrubá P, Češka R, Vrablík M.

Med Sci Monit. 2015 May 20;21:1454-9. doi: 10.12659/MSM.893007.

8.

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M; Clinical Pharmacogenomics Implementation Consortium (CPIC).

Clin Pharmacol Ther. 2012 Jul;92(1):112-7. doi: 10.1038/clpt.2012.57. Epub 2012 May 23.

9.

SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink.

Carr DF, O'Meara H, Jorgensen AL, Campbell J, Hobbs M, McCann G, van Staa T, Pirmohamed M.

Clin Pharmacol Ther. 2013 Dec;94(6):695-701. doi: 10.1038/clpt.2013.161. Epub 2013 Aug 13.

10.

Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies.

Hou Q, Li S, Li L, Li Y, Sun X, Tian H.

Medicine (Baltimore). 2015 Sep;94(37):e1268. doi: 10.1097/MD.0000000000001268.

11.

[Genetic marker of statin-induced rhabdomyolysis].

Chiba K, Morimoto K.

Yakugaku Zasshi. 2011 Feb;131(2):247-53. Review. Japanese.

12.

Evidence-based management of statin myopathy.

Harper CR, Jacobson TA.

Curr Atheroscler Rep. 2010 Sep;12(5):322-30. doi: 10.1007/s11883-010-0120-9. Review.

PMID:
20628837
13.

Lymphotoxin 252A>G polymorphism is common and associates with myocardial infarction in patients with rheumatoid arthritis.

Panoulas VF, Nikas SN, Smith JP, Douglas KM, Nightingale P, Milionis HJ, Treharne GJ, Toms TE, Kita MD, Kitas GD.

Ann Rheum Dis. 2008 Nov;67(11):1550-6. doi: 10.1136/ard.2007.082594. Epub 2008 Jan 29.

PMID:
18230628
14.

Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.

Generaux GT, Bonomo FM, Johnson M, Doan KM.

Xenobiotica. 2011 Aug;41(8):639-51. doi: 10.3109/00498254.2011.562566. Epub 2011 Mar 22. Review.

PMID:
21425956
15.

Use of statins is associated with an increased risk of rheumatoid arthritis.

de Jong HJ, Klungel OH, van Dijk L, Vandebriel RJ, Leufkens HG, van der Laan JW, Cohen Tervaert JW, van Loveren H.

Ann Rheum Dis. 2012 May;71(5):648-54. doi: 10.1136/ard.2011.155622. Epub 2011 Oct 6.

PMID:
21979000
16.

Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis.

Panoulas VF, Douglas KM, Smith JP, Taffé P, Stavropoulos-Kalinoglou A, Toms TE, Elisaf MS, Nightingale P, Kitas GD.

Endothelium. 2008 Jul-Aug;15(4):203-12. doi: 10.1080/10623320802228708.

PMID:
18663623
17.

Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization.

Shanahan RL, Kerzee JA, Sandhoff BG, Carroll NM, Merenich JA.

Pharmacotherapy. 2005 Mar;25(3):345-51.

PMID:
15843281
19.

Simvastatin-induced myopathy with concomitant use of cyclosporine: case report.

Yang WH, Zeng ZS, Ren XW, Li YP, Shang WJ, Feng GW, Zhang LR.

Int J Clin Pharmacol Ther. 2011 Dec;49(12):772-7.

PMID:
22122820
20.

The SLCO1B1*5 genetic variant is associated with statin-induced side effects.

Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS.

J Am Coll Cardiol. 2009 Oct 20;54(17):1609-16. doi: 10.1016/j.jacc.2009.04.053.

Items per page

Supplemental Content

Write to the Help Desk